APPENDICES. A systematic review and economic model of the ...

326
Appendix 12
Core symptoms Educational performance Quality of life Adverse events
[Confidential information removed]
Conclusions Authors’ conclusions: [Confidential information removed]
Reviewer’s comments: [Confidential information removed]
Study Intervention Participants Outcomes
Core symptoms
Abbreviated CTRS: total score
On-task behaviour
Reference
Rapport et al., 1989 85
Co-existent problems
Not reported
Arm 1
MPH
5 mg (range: 0.14–0.22 mg/kg); once
daily (breakfast)
(Individual administering medication
not reported)
Source
CCOHTA Report
Educational performance
Academic efficiency score
Inclusion criteria
1. ADHD using DSM-III-R criteria
2. Maternal report of a developmental history consistent with ADHD
3. 2 SD above mean on the Werry–Weiss–Peters Activity Scale (maternal
rating)
4. ACTRS > 15 (teacher rating)
5. No gross neurological, sensory or motor impairment
6. No current medication
Setting
USA
Psychological function
Not reported
Arm 2
MPH
10 mg (range: 0.28–0.44 mg/kg); once
daily (breakfast)
(Individual administering medication
not reported)
Design
Crossover trial
Diagnostic criteria
DSM-III-R
Depression or anxiety
Not reported
Number
Total randomised = 45 (male = 45)
No withdrawals reported
Quality of life
Not reported
Age
7.8 years (mean); 5–15 years (range), 1.5 years (SD)
Adverse events
Not reported
IQ
100 (mean)
Arm 3
MPH
15 mg (range: 0.42–0.66 mg/kg); once
daily (breakfast)
(Individual administering medication
not reported)
Additional outcomes
Not reported
Co-morbid disorders
Not reported
Duration
Treatment periods: 6
consecutive days;
washout period: 1 day
Purpose
To examine directly the
dose–response
relationship between
MPH and gross body
weight in a large sample
of children with ADHD
Diagnostic subtypes
Not reported
Arm 4
MPH
20 mg (range: 0.56–0.88 mg/kg); once
daily (breakfast)
(Individual administering medication
not reported)
Additional information
Randomisation method:
Three groups of 15 children were each randomised: low-weight group
(22–26 kg), mid-weight group (27–31 kg), high-weight group (32–36 kg)
Concurrent medication:
Participants were required not to be receiving concurrent medication